RxDoctor Payments Data

Mai Phan, MD

Internal Medicine · Reseda, CANPI 1306879283

Payments from drug & device makers

$2,051in general payments, 2019–2025

Across 86 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$459
  • Johnson & Johnson$314
  • AstraZeneca$233
  • Regeneron Healthcare Solutions, Inc.$190
  • Sun Pharmaceutical Industries Inc.$186
  • Covidien LP$92
  • plus $578 from 14 others

What the payments were for

  • Food & beverage$2,051100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,051 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$33,253
Medicare patients
91
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol428$421,099
JanuviaSitagliptin Phosphate330$341,151
JanumetSitagliptin Phos/Metformin Hcl173$172,178
JardianceEmpagliflozin135$149,725
OzempicSemaglutide72$96,665
Enbrel SureclickEtanercept14$95,510
EliquisApixaban54$65,008
ProliaDenosumab35$53,647
Dupixent PenDupilumab11$49,878
Celecoxib397$47,612
TrulicityDulaglutide27$43,978
VascepaIcosapent Ethyl85$41,241
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$36,167
RybelsusSemaglutide22$32,107
TradjentaLinagliptin39$28,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$27$519,020514 claims
AstraZenecaFarxiga$233$421,099428 claims
PfizerEliquis$88$65,00854 claims
AmgenProlia$13$53,64735 claims
AbbVieRestasis Multidose, Restasis$74$40,39040 claims
GSKTrelegy Ellipta$39$36,16730 claims
Johnson & JohnsonXarelto$314$28,33525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Reseda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →